Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands

References

• Aas T, Borresen A L, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug J E, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811–814
   PubMed Web of Science ®Google Scholar
• El Rouby S, Thomas A, Costin D, Rosenberg C R, Potmesil M, Silber R, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Barratt P L, Seymour M T, Stenning S P, Georgiades I, Walker C, Birbeck K, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002; 360: 1381–1391
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452–453
   PubMed Web of Science ®Google Scholar
• Muller M R, Tsakou G, Grunebach F, Schmidt S M, Brossart P. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 2004; 103: 1763–1769
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Wolbers J O, Smit W M, Schaafsma M R, Barge R M, Willemze R, et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia 2004; 18: 1278–1287
   PubMed Web of Science ®Google Scholar
• Tolba K A, Bowers W J, Hilchey S P, Halterman M W, Howard D F, Giuliano R E, et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 2001; 98: 287–295
   PubMed Web of Science ®Google Scholar
• Wierda W G, Cantwell M J, Woods S J, Rassenti L Z, Prussak C E, Kipps T J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917–2924
   PubMed Web of Science ®Google Scholar
• Mackus W J, Frakking F N, Grummels A, Gamadia L E, De Bree G J, Hamann D, et al. Expansion of CMV-specific CD8 + CD45RA +. Blood 2003; 102: 1057–1063
   PubMed Web of Science ®Google Scholar
• Kater A P, Remmerswaal E B, Nolte M A, Eldering E, Van Oers M H, van Lier R A. Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol 2004; 126: 512–516
   PubMed Web of Science ®Google Scholar
• Mous R, Savage P, Remmerswaal E B, van Lier R A, Eldering E, Van Oers M H. Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. Leukemia 2006; 20: 1096–1102
   PubMed Web of Science ®Google Scholar
• Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De P L, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–608
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med 1989; 320: 1420–1421
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry M R, Ward S, Brett S J, Castello-Cortes A, Brunner M D, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018–1028
   PubMed Web of Science ®Google Scholar
• Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 294–317
   PubMed Web of Science ®Google Scholar
• Schultz J, Lin Y, Sanderson J, Zuo Y, Stone D, Mallett R, et al. A tetravalent single-chain antibody–streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res 2000; 60: 6663–6669
   PubMed Web of Science ®Google Scholar
• Dhein J, Walczak H, Baumler C, Debatin K M, Krammer P H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995; 373: 438–441
   PubMed Web of Science ®Google Scholar
• Picker L J, Singh M K, Zdraveski Z, Treer J R, Waldrop S L, Bergstresser P R, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995; 86: 1408–1419
   PubMed Web of Science ®Google Scholar
• Choudhuri K, Wiseman D, Brown M H, Gould K, van der Merwe P A. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 2005; 436: 578–582
   PubMed Web of Science ®Google Scholar
• Leupin O, Zaru R, Laroche T, Muller S, Valitutti S. Exclusion of CD45 from the T-cell receptor signaling area in antigen-stimulated T lymphocytes. Curr Biol 2000; 10: 277–280
   PubMed Web of Science ®Google Scholar
• Oettgen H C, Terhorst C, Cantley L C, Rosoff P M. Stimulation of the T3-T cell receptor complex induces a membrane-potential-sensitive calcium influx. Cell 1985; 40: 583–590
   PubMed Web of Science ®Google Scholar
• van Kemenade F J, Kuijpers K C, de Waal-Malefijt R, van Lier R A, Miedema F. Skewing to the LFA-3 adhesion pathway by influenza infection of antigen-presenting cells. Eur J Immunol 1993; 23: 635–639
   PubMed Web of Science ®Google Scholar
• Chavin K D, Qin L, Yon R, Lin J, Yagita H, Bromberg J S. Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade. J Immunol 1994; 152: 3729–3739
   PubMed Web of Science ®Google Scholar
• Gorog G, Batory G, Laskay T, Petranyi G G. Effect of anti-human pan-T monoclonal antibodies on lymphocyte proliferative and cytotoxic functions. Cell Immunol 1985; 96: 184–198
   PubMed Web of Science ®Google Scholar
• Selvaraj P, Plunkett M L, Dustin M, Sanders M E, Shaw S, Springer T A. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987; 326: 400–403
   PubMed Web of Science ®Google Scholar
• Shaw S, Luce G E, Quinones R, Gress R E, Springer T A, Sanders M E. Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature 1986; 323: 262–264
   PubMed Web of Science ®Google Scholar
• Espagnolle N, Depoil D, Zaru R, Demeur C, Champagne E, Guiraud M, et al. CD2 and TCR synergize for the activation of phospholipase Cgamma1/calcium pathway at the immunological synapse. Int Immunol 2007; 19: 239–248
   PubMed Web of Science ®Google Scholar
• Zaru R, Cameron T O, Stern L J, Muller S, Valitutti S. Cutting edge: TCR engagement and triggering in the absence of large-scale molecular segregation at the T cell-APC contact site. J Immunol 2002; 168: 4287–4291
   PubMed Web of Science ®Google Scholar
• Khanna R, Burrows S R, Suhrbier A, Jacob C A, Griffin H, Misko I S, et al. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J Immunol 1993; 150: 5154–5162
   PubMed Web of Science ®Google Scholar
• van der Merwe P A, McNamee P N, Davies E A, Barclay A N, Davis S J. Topology of the CD2-CD48 cell-adhesion molecule complex: implications for antigen recognition by T cells. Curr Biol 1995; 5: 74–84
   PubMed Web of Science ®Google Scholar
• Li J, Smolyar A, Sunder-Plassmann R, Reinherz E L. Ligand-induced conformational change within the CD2 ectodomain accompanies receptor clustering: implication for molecular lattice formation. J Mol Biol 1996; 263: 209–226
   PubMed Web of Science ®Google Scholar
• Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Muller S, et al. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci USA 2003; 100: 14145–14150
   PubMed Web of Science ®Google Scholar
• Almasri N M, Duque R E, Iturraspe J, Everett E, Braylan R C. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40: 259–263
   PubMed Web of Science ®Google Scholar
• Bertram E M, Dawicki W, Sedgmen B, Bramson J L, Lynch D H, Watts T H. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol 2004; 172: 981–988
   PubMedGoogle Scholar
• Freedman A S. Immunobiology of chronic lymphocytic leukemia. Hematol Oncol Clin North Am 1990; 4: 405–429
   PubMed Web of Science ®Google Scholar
• Fayad L Keating M J, Reuben J M, O'Brien S, Lee B N, Lerner S, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256–263
   PubMed Web of Science ®Google Scholar
• Buschle M, Campana D, Carding S R, Richard C, Hoffbrand A V, Brenner M K. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177: 213–218
   PubMed Web of Science ®Google Scholar
• Jahrling P B, Hensley L E, Martinez M J, Leduc J W, Rubins K H, Relman D A, et al. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci USA 2004; 101: 15196–15200
   PubMed Web of Science ®Google Scholar